[HTML][HTML] Longer-term effects of cardiac telerehabilitation on patients with coronary artery disease: systematic review and meta-analysis
W Zhong, R Liu, H Cheng, L Xu, L Wang… - JMIR mHealth and …, 2023 - mhealth.jmir.org
Background Cardiac telerehabilitation offers a flexible and accessible model for patients
with coronary artery disease (CAD), effectively transforming the traditional cardiac …
with coronary artery disease (CAD), effectively transforming the traditional cardiac …
[Retracted] Changes in the Quality of Life, Psychological Status, Medication Compliance, and Prognosis of Patients with Acute Myocardial Infarction after PCI by …
Y Li, M Hong, G Liu - Evidence‐Based Complementary and …, 2021 - Wiley Online Library
Objective. To discuss the changes in the quality of life, psychological status, medication
compliance, and prognosis of patients with acute myocardial infarction (AMI) after …
compliance, and prognosis of patients with acute myocardial infarction (AMI) after …
How do lipoprotein (a) concentrations affect clinical outcomes for patients with stable coronary artery disease who underwent different dual antiplatelet therapy after …
K Cui, D Yin, C Zhu, W Song, H Wang… - Journal of the …, 2022 - Am Heart Assoc
Background Lp (a)(lipoprotein [a]) plays an important role in predicting cardiovascular
events in patients with coronary artery disease through its proatherogenic and prothrombotic …
events in patients with coronary artery disease through its proatherogenic and prothrombotic …
Benefit and risk of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents in patients with elevated lipoprotein (a) …
K Cui, HY Wang, D Yin, C Zhu, W Song… - Frontiers in …, 2021 - frontiersin.org
Background: Lipoprotein (a) is positively related to cardiovascular events in patients with
coronary artery disease (CAD). Given that lipoprotein (a) has a prothrombotic effect …
coronary artery disease (CAD). Given that lipoprotein (a) has a prothrombotic effect …
Impact of Lipoprotein (a) concentrations on long-term cardiovascular outcomes in patients undergoing percutaneous coronary intervention: A large cohort study
K Cui, D Yin, C Zhu, S Yuan, S Wu, L Feng… - Nutrition, Metabolism and …, 2022 - Elsevier
Background and aims Till now, the prognostic value of lipoprotein (a)[Lp (a)] in patients with
coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) …
coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) …
Diabetes and outcomes following personalized antiplatelet therapy in coronary artery disease patients who have undergone PCI
YY Zheng, TT Wu, Y Yang, XG Hou… - The Journal of …, 2022 - academic.oup.com
Context A personalized antiplatelet therapy guided by a novel platelet function testing (PFT),
PL-12, is considered an optimized treatment strategy in stable coronary artery disease …
PL-12, is considered an optimized treatment strategy in stable coronary artery disease …
[HTML][HTML] Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
J Han, Y Zhang, X Shi, B Lin, Y Zhang, R Zhang… - Global Heart, 2023 - ncbi.nlm.nih.gov
Objective: It remains controversial whether to extend the course of dual antiplatelet therapy
(DAPT) after percutaneous coronary intervention (PCI). We conducted a study to investigate …
(DAPT) after percutaneous coronary intervention (PCI). We conducted a study to investigate …
Duration and clinical outcomes of dual antiplatelet therapy following percutaneous coronary intervention for acute coronary syndrome: A multicentre “real-world …
CE Vergara-Uzcategui, VH Moreno… - Frontiers in …, 2023 - frontiersin.org
Background The optimal duration of dual antiplatelet therapy (DAPT) ought to be determined
taking into account individual ischaemic or bleeding events risks. To date, studies have …
taking into account individual ischaemic or bleeding events risks. To date, studies have …